Scientech Research LLC Altimmune, Inc. Call Options Transaction History
Scientech Research LLC
- $409 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALT
# of Institutions
213Shares Held
35.1MCall Options Held
4.92MPut Options Held
4.18M-
Black Rock Inc. New York, NY5.32MShares$21.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.17MShares$20.5 Million0.0% of portfolio
-
State Street Corp Boston, MA2.75MShares$10.9 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$10.9 Million0.64% of portfolio
-
Geode Capital Management, LLC Boston, MA1.93MShares$7.66 Million0.0% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $194M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...